ImmunityBio (NASDAQ:IBRX) Trading 41.9% Higher – Should You Buy?

ImmunityBio, Inc. (NASDAQ:IBRX) rose 41.9% during trading on Wednesday . The company traded as high as $8.68 and last traded at $8.54. Approximately 79,194,862 shares changed hands during trading, an increase of 87% from the average daily volume of 42,421,027 shares. The stock had previously closed at $6.02.

ImmunityBio News Roundup

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: European Commission authorization expands ImmunityBio’s commercial footprint across four regulatory jurisdictions quickly, including key markets and additional indications for Anktiva — a major growth catalyst for sales and addressable market. What’s Behind The Jump In ImmunityBio Stock?
• Positive Sentiment: Productive regulatory discussions and a Saudi filing/“nod” for bladder cancer (BCG-related) advance market access in Saudi Arabia — investors view this as near-term revenue upside and validation in a large, well-funded market. ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority
• Positive Sentiment: Market coverage and pre-market headlines highlighted the Saudi BCG update and growing retail interest, amplifying buying momentum. Analyst support (D. Boral Capital reaffirmed buy with a $24 PT) provides a bullish price-target narrative. How high can IBRX stock go now?
• Neutral Sentiment: Commercial performance context: Seeking Alpha notes Anktiva’s strong early commercial traction (FY25 revenue cited) and upcoming pivotal trial readouts (bladder cancer, glioblastoma) — these are major potential upside catalysts but also make valuation sensitive to trial setbacks. ImmunityBio: The Story Surrounding Anktiva So Far
• Neutral Sentiment: Reported short-interest data is anomalous/unclear (entries show zero shares / NaN); with very high trading volume, short-interest metrics may not reflect real positioning — monitor updated, reliable short-interest reports for true bearish pressure. Short Interest Data (company reports)
• Negative Sentiment: Pomerantz law firm announced an investigation on behalf of ImmunityBio investors — potential litigation or disclosure risk that could create headline-driven volatility and act as a near-term overhang. Pomerantz Law Firm Investigates Claims

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on IBRX. HC Wainwright lifted their price target on shares of ImmunityBio from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. D. Boral Capital restated a “buy” rating and set a $24.00 target price on shares of ImmunityBio in a research note on Tuesday. BTIG Research lifted their target price on ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Piper Sandler increased their price target on ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Finally, Jefferies Financial Group raised their price objective on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.80.

ImmunityBio Stock Performance

The business’s 50 day moving average price is $4.10 and its 200-day moving average price is $2.99. The firm has a market cap of $8.41 billion, a price-to-earnings ratio of -20.83 and a beta of 0.16.

Insider Activity at ImmunityBio

In related news, Director Barry J. Simon sold 151,967 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $7.20, for a total transaction of $1,094,162.40. Following the sale, the director directly owned 3,091,604 shares of the company’s stock, valued at approximately $22,259,548.80. This represents a 4.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Christobel Selecky sold 25,000 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $7.51, for a total value of $187,750.00. The disclosure for this sale is available in the SEC filing. Insiders have sold 226,967 shares of company stock worth $1,531,912 in the last 90 days. 69.48% of the stock is currently owned by insiders.

Institutional Trading of ImmunityBio

Several institutional investors have recently added to or reduced their stakes in IBRX. Armistice Capital LLC acquired a new stake in ImmunityBio in the 2nd quarter valued at approximately $20,497,000. AlphaCore Capital LLC bought a new position in shares of ImmunityBio in the second quarter worth $7,854,000. Geode Capital Management LLC grew its stake in shares of ImmunityBio by 34.7% in the second quarter. Geode Capital Management LLC now owns 5,777,269 shares of the company’s stock worth $15,254,000 after purchasing an additional 1,487,849 shares in the last quarter. Chicago Partners Investment Group LLC acquired a new position in shares of ImmunityBio during the second quarter valued at $70,000. Finally, CWM LLC increased its holdings in shares of ImmunityBio by 849.2% during the second quarter. CWM LLC now owns 48,715 shares of the company’s stock valued at $129,000 after purchasing an additional 43,583 shares during the period. Institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.